Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2018 Sep 19. pii: clincanres.1912.2018. doi: 10.1158/1078-0432.CCR-18-1912. [Epub ahead of print]

PMID:
30232224
2.

Low-Dose Abiraterone With Food: Rebutting an Editorial.

Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 Sep 6:JCO2018793018. doi: 10.1200/JCO.2018.79.3018. [Epub ahead of print] No abstract available.

PMID:
30188785
3.

Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.

Szmulewitz RZ, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 Sep 6:JCO2018793190. doi: 10.1200/JCO.2018.79.3190. [Epub ahead of print] No abstract available.

PMID:
30188784
4.

MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease.

Bhanvadia RR, VanOpstall C, Brechka H, Barashi NS, Gillard M, McAuley EM, Vasquez JM, Paner G, Chan WC, Andrade J, De Marzo AM, Han M, Szmulewitz RZ, Vander Griend DJ.

Clin Cancer Res. 2018 Aug 1;24(15):3668-3680. doi: 10.1158/1078-0432.CCR-17-3673. Epub 2018 May 1.

PMID:
29716922
5.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

PMID:
29590007
6.

Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.

Kach J, Long TM, Selman P, Tonsing-Carter EY, Bacalao MA, Lastra RR, de Wet L, Comiskey S, Gillard M, VanOpstall C, West DC, Chan WC, Griend DV, Conzen SD, Szmulewitz RZ.

Mol Cancer Ther. 2017 Aug;16(8):1680-1692. doi: 10.1158/1535-7163.MCT-16-0923. Epub 2017 Apr 20.

7.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma.

Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WM.

Clin Genitourin Cancer. 2017 Apr;15(2):207-212. doi: 10.1016/j.clgc.2016.08.011. Epub 2016 Aug 17.

8.

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.

Kregel S, Chen JL, Tom W, Krishnan V, Kach J, Brechka H, Fessenden TB, Isikbay M, Paner GP, Szmulewitz RZ, Vander Griend DJ.

Oncotarget. 2016 May 3;7(18):26259-74. doi: 10.18632/oncotarget.8456.

9.

Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer.

Reyes EE, Gillard M, Duggan R, Wroblewski K, Kregel S, Isikbay M, Kach J, Brechka H, Weele DJ, Szmulewitz RZ, Griend DJ.

J Transl Sci. 2015 Jul;1(1). pii: http://oatext.com/Molecular-analysis-of-CD133-positive-circulating-tumor-cells-from-patients-with-metastatic-castration-resistant-prostate-cancer.php. Epub 2015 Jul 30.

10.

Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.

Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL 3rd, Shen J, Gururajan M, Sievert M, Stadler WM.

Prostate. 2016 Feb 15;76(3):286-93. doi: 10.1002/pros.23119. Epub 2015 Oct 23.

11.

Targeting the glucocorticoid receptor in breast and prostate cancers.

Kach J, Conzen SD, Szmulewitz RZ.

Sci Transl Med. 2015 Sep 16;7(305):305ps19. doi: 10.1126/scitranslmed.aac7531.

12.

Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report.

VanderWeele DJ, Paner GP, Fleming GF, Szmulewitz RZ.

Front Oncol. 2015 Jul 22;5:169. doi: 10.3389/fonc.2015.00169. eCollection 2015.

13.

Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer.

Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, Stadler WM, Vander Griend DJ, Szmulewitz RZ.

J Transl Med. 2014 Nov 26;12:313. doi: 10.1186/s12967-014-0313-z.

14.

Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.

Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ.

Clin Cancer Res. 2014 Dec 15;20(24):6269-76. doi: 10.1158/1078-0432.CCR-14-1595. Epub 2014 Oct 21.

15.

The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.

Kregel S, Szmulewitz RZ, Vander Griend DJ.

Prostate. 2014 Nov;74(15):1530-43. doi: 10.1002/pros.22870. Epub 2014 Aug 31.

16.

Corticosteroids and prostate cancer: friend or foe?

Geynisman DM, Szmulewitz RZ, Plimack ER.

Eur Urol. 2015 May;67(5):874-5. doi: 10.1016/j.eururo.2014.08.008. Epub 2014 Aug 20. No abstract available.

PMID:
25151018
17.

Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms.

Cohen A, Richards KA, Patel S, Weiner A, Eggener SE, Szmulewitz RZ.

Urol Oncol. 2015 Feb;33(2):70.e1-7. doi: 10.1016/j.urolonc.2014.06.006. Epub 2014 Jul 16.

PMID:
25044254
18.

Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate.

Weiner AB, Patel SG, Richards KA, Szmulewitz RZ, Eggener SE.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):286-91. doi: 10.1038/pcan.2014.26. Epub 2014 Jul 15.

PMID:
25027862
19.

Vemurafenib oral bioavailability: an insoluble problem.

Szmulewitz RZ, Ratain MJ.

J Clin Pharmacol. 2014 Apr;54(4):375-7. No abstract available.

PMID:
24757719
20.

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.

Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ.

Horm Cancer. 2014 Apr;5(2):72-89. doi: 10.1007/s12672-014-0173-2. Epub 2014 Mar 11.

21.

National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.

Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SE.

Cancer. 2014 May 15;120(10):1491-8. doi: 10.1002/cncr.28600. Epub 2014 Feb 12.

22.

Playing Russian roulette with tyrosine kinase inhibitors.

Szmulewitz RZ, Ratain MJ.

Clin Pharmacol Ther. 2013 Mar;93(3):242-4. doi: 10.1038/clpt.2012.245. Epub 2012 Dec 18. No abstract available.

PMID:
23340477
23.

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.

Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ, Vander Griend DJ.

PLoS One. 2013;8(1):e53701. doi: 10.1371/journal.pone.0053701. Epub 2013 Jan 11.

24.

A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer.

Geynisman DM, Szmulewitz RZ, Stadler WM.

Eur Urol. 2012 Nov;62(5):864-6. doi: 10.1016/j.eururo.2012.08.030. Epub 2012 Aug 25. No abstract available.

PMID:
22939385
25.

A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study.

Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EM.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):87-92. doi: 10.1038/pcan.2011.49. Epub 2011 Oct 18.

26.

Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.

Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen SD.

Prostate. 2012 Feb 1;72(2):157-64. doi: 10.1002/pros.21416. Epub 2011 May 11.

27.

Metastasis-suppressor genes in clinical practice: lost in translation?

Shoushtari AN, Szmulewitz RZ, Rinker-Schaeffer CW.

Nat Rev Clin Oncol. 2011 Jun;8(6):333-42. doi: 10.1038/nrclinonc.2011.65. Epub 2011 Apr 26. Review.

PMID:
21522123
28.

MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression.

Szmulewitz RZ, Clark R, Lotan T, Otto K, Taylor Veneris J, Macleod K, Rinker-Schaeffer C.

Int J Cancer. 2012 Feb 1;130(3):509-20. doi: 10.1002/ijc.26005. Epub 2011 Apr 25.

29.

Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies.

Jayram G, Szmulewitz RZ, Eggener SE.

Indian J Urol. 2010 Jan-Mar;26(1):92-7. doi: 10.4103/0970-1591.60449.

30.

New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells.

Taylor JL, Szmulewitz RZ, Lotan T, Hickson J, Griend DV, Yamada SD, Macleod K, Rinker-Schaeffer CW.

Cancer Lett. 2008 Dec 8;272(1):12-22. doi: 10.1016/j.canlet.2008.05.012. Epub 2008 Jun 24. Review.

PMID:
18572308
31.

Sunitinib--a new standard of care for metastatic renal cell carcinoma.

Stadler WM, Szmulewitz RZ.

Nat Clin Pract Oncol. 2007 Aug;4(8):458-9. Epub 2007 Jun 26. No abstract available.

PMID:
17593923

Supplemental Content

Loading ...
Support Center